SK Biopharmaceuticals Discloses 2026 Corporate Governance Report – Strong Governance with Majority Outside Directors and All-Outside Audit Committee, No Dividend
Board of 7 directors (4 outside, 57.1%), audit committee composed entirely of outside directors ensures independence
Separation of CEO and board chair, with an outside director as chair strengthens oversight
Accumulated deficit of 350.3B KRW on separate basis; no dividends or share buybacks
CEO succession policy in place but not fully documented
Non-compliance with 4-week prior convocation notice for AGM; no dividend predictability
Internal accounting control system received unqualified opinion; ISO 37001 anti-bribery system adopted
[AI Summary]This report indicates strong governance structure, but lack of dividend and shareholder return policy limits shareholder value improvement, resulting in a neutral impact.